Abstract: Anti-angiogenesis agent-linked liposomes and micelles, methods of making such liposomes and micelles, and methods of using such liposomes and micelles, such as for delivery of therapeutic and detection agents to tumor cells, are described.

Abstract: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

Abstract: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.

Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.

Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Abstract: Nanonized formulations of testosterone esters, especially testosterone undecanoate, and of testosterone are prepared which show an enhanced oral bioavailability compared to the existing oral products on the market. The drug is dissolved in a melted lipid phase, which is subsequently nanonized. The drug is associated with the lipid. The drug can also be nanonized without having lipid present yielding nanocrystals. The nanonized drug can be incorporated into tablets or capsules for oral administration, typically one unit is sufficient for delivery of a single dose.

Abstract: The invention provides a block copolypeptide comprising a hydrophilic heteropolypeptide block (A) and a hydrophobic homopolypeptide block (B). There is also provided a polymersome comprising a block copolypeptide of the invention. The invention further provides a method for preparing a copolymer comprising ring-opening polymerisation (ROP) of an amino acid N-carboxyanhydride (NCA) initiated from a peptide.

Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.

Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Abstract: Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the present invention provides for a pharmaceutical composition that includes a therapeutically effective amount of testosterone undecanoate and a solubilizer. The testosterone undecanoate is solubilized in the composition and is present in an amount such that it comprises about 14 wt % to about 35 wt % of the total composition.

Abstract: The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded particulates are present as a discontinuous phase in said matrix.

Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.

Abstract: A sustained release formulation for opioid drugs is described. The formulation contains an opioid-ion exchange resin complex having a hybrid coating. The hybrid coating contains a cured polyvinylacetate polymer and a pH-dependent enteric coating layer mixed therein. Also provided are methods of making and using same.

Abstract: A xanthine oxidase inhibitor for use in the treatment of angina is described. The angina may be stable angina pectoris and the treatment may be to eliminate, reduce or alleviate one or more symptoms of angina pectoris (such as chest pain), or may be prophylactic. The xanthine oxidase inhibitor may be used in combination with one or more additional therapeutic agents, such as anti-anginal agents. Pharmaceutical compositions, medicaments and kits for the treatment of angina are also described.

Abstract: A modified release dosage form for the oral administration of tranexamic acid.

Abstract: The invention provides core-shell magnetic particles comprising a magnetic core and a functional shell, methods for making same, methods of separation using same, methods for using same, and devices comprising same. The particles and methods of the invention are useful for targeting and removing substances of interest that may be found in complex mixtures.

Abstract: In the field of drug or nutrient administration novel particles and formulations thereof are provided. Said particles each have a core comprising active agent and at least partial coating comprising proteins, selected from hydrophobins. Preferable hydrophobins belong to class I or class II. Said particles exhibit enhanced characteristics, for example dispersibility or solubility. Here is also disclosed two methods for producing said particles in nanoscale, of which one utilizes precipitating and another wet milling.

Abstract: The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.

Abstract: A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance.

Abstract: The invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of viral diseases of the eye.

Abstract: A method and composition for a non-toxic aqueous silicon solution.

Abstract: A composite biocompatible hydrogel material includes a porous polymer matrix, the polymer matrix including a plurality of pores and providing a Young's modulus of at least 10 GPa. A calcium comprising salt is disposed in at least some of the pores. The porous polymer matrix can comprise cellulose, including bacterial cellulose. The composite can be used as a bone graft material. A method of tissue repair within the body of animals includes the steps of providing a composite biocompatible hydrogel material including a porous polymer matrix, the polymer matrix including a plurality of pores and providing a Young's modulus of at least 10 GPa, and inserting the hydrogel material into cartilage or bone tissue of an animal, wherein the hydrogel material supports cell colonization in vitro for autologous cell seeding.

Abstract: The present invention relates to topical compositions containing choline alfoscerate for use in maintaining and restoring the integrity of the mucous membranes.

Abstract: A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the following formula or its salt: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n is 1, 2, 3 or 4; R1 is a substitutable alkyl group, R2? is a substitutable alkyl group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group or a hydroxyl group, p is 1, 2 or 3, and R2? is a substitutable alkoxy group or a hydroxyl group, provided that at least two of R2? and R2? optionally form a condensed ring containing an oxygen atom and (b) at least one other fungicide.

Abstract: The present invention provides, e.g., compounds having the structure of formula (I): The present invention also provides pharmaceutical compositions that include such compounds, and methods for modulating murine double minute 2 protein (Mdm2) E3 ligase activity, particularly the Mdm2-MdmX hetero-complex E3 ligase activity, using such compounds.

Abstract: The invention provides a solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N×an amount of flavouring; and (g) optionally N×an amount of sweetener where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.

Abstract: The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and/or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

Abstract: Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. In some embodiments, the compound is a N6-modified adenosine compound. Methods of screening for and methods of using the compounds are also provided.

Abstract: The present invention discloses a soap composition containing a ginseng absolute oil, based on the finding that a ginseng extract, particularly a ginseng absolute oil, has a potent effect on the treatment of acne. A soap composition for treating acne according to one embodiment of the present invention was used, and as a result, it could be seen that the soap composition exhibited excellent effects of removing sebum and killing acne bacteria to prevent proliferation of the bacteria and infection with the bacteria, thus exhibiting a potent effect on the treatment of acne.

Abstract: The present invention relates to bioactivity-guided isolation and identification of bioactive compounds from oregano and mint plants, in particular, rosmarinic acid, oleanolic acid and ursolic acid, and use of these compounds or combinations thereof as anti-inflammatory agents for the treatment of conditions related to pain and inflammation and/or as ingredients of dietary supplements. The invention also relates to optimization of the methods for qualitative and quantitative analysis of the bioactive compounds in oregano and mint plants. In particular, this invention introduces an LC/MS (SIM mode) method to achieve co-quantitation of the three organic acids using a unique tandem column system. In addition, the invention also relates to the methods for recovering various water-soluble polyphenols and triterpenes from aromatic plants.

Abstract: An apparatus and method are disclosed for manufacturing an electrical connector. A mold is presented having a pair of opposing dies that each define a mold pocket. The mold pockets of each die can be joined to form a mold cavity. Plastic can be injection molded into the mold cavity to form an electrical connector housing.

Abstract: The compact resin molding machine is capable of efficiently performing a sequence of molding actions from feeding a work and resin to accommodating the molded work. The resin molding machine comprises: a work conveying mechanism including a robot, which has a robot hand for holding the work and which is capable of rotating and linearly moving; a work feeding section for feeding the work; a resin feeding section for feeding the resin; a press section including a molding die set, in which the work is resin-molded; a work accommodating section for accommodating the molded work; and a control section controlling the entire resin molding machine. The work feeding section, the resin feeding section, the press section and the work accommodating section are located to enclose a moving area of the robot of the work conveying mechanism.

Abstract: The invention relates to an arrangement and to a method for the electromechanical drive for mold closing systems and calibration blow mandrel systems in blow molding machines, wherein the arrangement for the drive of an extrusion blow molding machine includes a push mechanism (3; 11), a push rod (4; 12) and exactly one electric motor (1; 9), wherein the push rod (4; 12) is movable by the push mechanism (3; 11) which is driven by the electric motor (1; 9), wherein the electric motor (1; 9) has an additional braking device (2; 10) which can be activated on the reaching of a required torque or a required force of the electric motor (2; 10) to hold the push rod (4; 12) in a state of maximum tension in its instantaneous position.

Abstract: An extruder screw segment has opposed end faces disposed at a non-orthogonal angle with respect to a rotation axis of the body.

Abstract: A compliant cover is placed over a part being molded in a molding process. The compliant cover is formed from a plurality of longitudinal cells positioned next to one another. At least one communication port is coupled to each longitudinal cell, and a source of fluid media at a preselected temperature is coupled to the communication ports whereby the longitudinal cells may be filled with the fluid media at the preselected temperature. The compliant cover may thus be used to selectively heat and cool the part being molded to decrease the time required by the part to rise to the temperature required to cure the resin in the part and to cool the part so that it can be removed from the mold.

Abstract: In order to achieve reduction of a space occupied in a plant for manufacturing pharmaceutical tablets or the like, there is provided a compression molding machine that includes a table, an upper punch and a lower punch, a molded product collection mechanism, a molded product reservoir, and a housing for accommodating a connection end of an air convey path connected to the molded product reservoir. In this configuration, there is no need to additionally provide a dust removing device or a lifter outside the machine.

Abstract: Disclosed is a molding device (10) for a machine for manufacturing containers, in particular bottles, made of a thermoplastic material by blow-molding or stretch blow-molding a preheated preform. The molding device (10) includes: two half-molds (14), each of which is provided with a half-cavity (16) and each of which includes a sealing surface (18) and an outer surface (20); two mold carriers (34), each of which has a recess (40) for receiving a corresponding half-mold (14); and an attachment element (44, 52) for removably attaching each half-mold (14) into the recess (40) of the corresponding mold carrier (34), characterized in that the attachment element (44, 52) is controlled by the attraction of the half-mold (14) against the back wall (42) of the recess (40) of the mold carrier (34).

Abstract: Disclosed herein is, amongst other things, a molding apparatus that includes a collet (116, 316) for use in a first stack portion (110, 310) of a mold stack (106, 306). The mold stack (106, 306) is associated, in use, with an injection mold (100). The collet (116, 316) is structured to define a plurality of molding fingers (140, 340) that are resiliently deflectable, in use, between a neutral configuration and a deflected configuration, the plurality of molding fingers (140, 340) being cooperable to define an encapsulated portion (145) of a molding cavity (101) when arranged in abutment. Furthermore, each of the plurality of molding fingers (140, 340) defines a cam follower (142, 342) that is cooperable, in use, with a bearing (170) with which to link the cam follower (142, 342) with a cam (150, 250) for the exercising thereof between the neutral configuration and the deflected configuration.

Abstract: A feeding regimen for an infant which includes (a) feeding to a newborn infant a first composition including a fat or lipid; a protein source, wherein the protein source has from about 72% to about 90% whey and from about 10% to about 28% casein; a prebiotic composition; and at least about 72 IU/100 kcal of vitamin D, and (b) feeding to a later stage infant a second composition which includes a fat or lipid; a protein source, wherein the protein source has from about 50% to about 70% whey and from about 30% to about 50% casein; a prebiotic composition; and no greater than 70 IU/100 kcal of vitamin D.

Abstract: A composition for increasing the bioavailability of oils in humans and animals comprising mixing a first emulsifier and a second emulsifier in a ratio ranging from about 1:1 to about 3:1 with a consumable oil wherein the first emulsifier is polyoxyethylene sorbitan monooleate and the second emulsifier is tocopheryl polyethylene glycol succinate. A method for increasing the bioavailability of such a composition is also provided.

Abstract: The present invention provides a technique of eating with the help of brain signals, said technique comprising of controlling the timing of the signals sent/received by the satiety and hunger centre of brain without the use of any external medications. This results in balanced control of the blood circulation to the vital organs of the body, so that proper functioning of organs is achieved and expression of genes is regulated resulting in prevention of metabolic diseases, obesity, malnutrition, metabolic syndrome, etc.

Abstract: The present invention includes a palatable, stable composition comprising a biomass hydrolysate emulsion for incorporation, into, or used as, nutritional products, cosmetic products or pharmaceutical products. Preferred sources for biomass are microbial sources, plant sources and animal sources. The present invention also provides methods for making such compositions, specifically, a method for producing a product comprising a nutrient, particularly a long chain polyunsaturated fatty acid, comprising hydrolyzing a biomass comprising the nutrient and emulsifying the hydrolyzed biomass. Such compositions and methods are useful, for example, for increasing intake of nutrients such as omega-3 long chain polyunsaturated fatty acids having 18 or more carbons.

Abstract: The present invention relates to a method of preparing a leavened bread dough, said method comprising the following sequence of processing steps: combining flour, water, yeast and/or leavening agent, and optionally one or more additional bakery ingredients to produce a dough-type mix; mixing and working the dough-type mix in a mixer to produce an underdeveloped dough with a density of 0.9-1.5 g/ml, the total energy input from the mixer into the underdeveloped dough during said mixing and working of the dough-type mix being at least 1 W.h/kg; further working a batch of at least 15 kg of the underdeveloped dough by subjecting it to deformation shear, thereby producing a developed dough; dividing the developed dough into two or more developed dough pieces having an individual mass of 30-3000 g; and leavening the developed dough pieces to yield leavened dough pieces having a specific volume of at least 2.0 ml/g; wherein the aforementioned sequence of processing steps is completed within 3 hours.

Abstract: Methods for the production of substrate, tuber, and grain compositions containing isomalto-oligosaccharides are described. The methods comprise (a) contacting a substrate, tuber or grain containing ungelatinized starch with a maltogenic enzyme and a starch liquefying enzyme to produce maltose; (b) contacting said maltose with a transglucosidic enzyme, wherein said steps (a) and step (b) occur at a temperature less than or at a starch gelatinization temperature; and (c) obtaining a substrate, grain or tuber composition having an enzymatically produced isomalto-oligosaccharide, wherein the oligosaccharide is derived from the grain. The maltogenic enzyme can be either exogenous or endogenous to the grain. The contacting steps can be sequential or concurrent. The present invention also describes flour, oral rehydrating solutions, beer adjuncts, food, feed, beverage additives incorporating the grain compositions made as described.

Abstract: A fiber extracted from a fruit or vegetable byproduct is provided, the extracted fiber having a molecular weight of between about 5000 grams/mol (g/mol) and about 8000 g/mol, or a pectic oligosaccharide having a molecular weight of between about 300 g/mol and 2500 g/mol. The fiber may be extracted using physical methods or a combination of a physical method to break the fruit or vegetable byproduct cell walls and enzymatic hydrolysis. Also, a comestible containing the extracted fiber is provided. A method for producing a soluble fiber is further provided including reducing the particle size of a fruit or vegetable byproduct, subjecting the byproduct particles to a physical process to break cell walls of the particles, adding one or more enzymes, mixing or agitating the particles, and filtering the byproduct particles to provide a retentate and a permeate. The permeate contains the soluble fiber, which is optionally a prebiotic fiber.

Abstract: It is possible to adjust the balance of taste of a low-salt food or beverage and to impart good taste to the low-salt food or beverage for general purposes without the need of imparting a salty taste to the low-salt food or beverage, by adding a hydrolysate of a plant-derived protein and an yeast extract are added to a low-salt food or beverage.

Abstract: By using phospholipase C and/or phospholipase D when producing a processed meat product, water content released while the processed meat product is stored can be suppressed without adversely affecting the texture, such as the hardness and flexibility, of the processed meat product.

Abstract: The invention relates to a method for preparing yeast, to a yeast obtained according to the method, to a food composition comprising the yeast, to an apparatus intended for implementing the method and to various uses of the yeast in a baker's dough. More specifically, the method consists in dehydrating yeast cream, granulating this yeast, and then drying.

Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, preservatives, and the like.